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Promote cheaper generic drugs to 
patients – and help contain medical 
inflation
The country’s top medical 
scheme administrator, Dis­
covery Health, calculates 
that far greater use of 
cheaper, good­quality gen­
eric drugs will drive down healthcare infla­
tion, saving as much as R1.5 billion per 
annum for medical scheme members  – 
while a major hospital group has begun 
promoting use of these medicines through 
its hospital pharmacies. 
This emerged at a pioneering day-
long medicine summit convened by the 
administration and managed healthcare 
giant in Sandton, Johannesburg, on 15 May 
this year and attended by representatives of 
the local and international pharmaceutical 
industry, private hospital executives and 
government drug regulation advisors. 
Setting the scene for the summit, Discovery 
Health CEO Jonny Broomberg challenged 
his predominantly drug-company audience 
to enter risk-sharing and ‘payment for value’ 
agreements, plus volume-based pricing, 
appealing to them to work with the National 
Department of Health (NDoH) to keep the 
cost of medicines affordable in the private 
sector. 
‘We often hear from you that the Depart-
ment of Health is not supportive of this 
risk-sharing agreement – my theory is that 
you guys are not sufficiently motivated to 
push this approach. We need to work harder 
with the NDoH to tackle inefficiencies and 
perversities throughout the medicine supply 
chain. It doesn’t make sense that many 
products, especially some generics, maintain 
such high prices and yet still have the largest 
market share. This defies market logic,’ he 
said. Relative to global benchmarks on drug 
pricing, South Africa (SA)’s private sector 
pricing was high and rigid, and he predicted 
that ‘the time of arbitrary high pricing because 
you can’ was coming to an end. 
Market ignoring 
competitively priced 
drugs – Broomberg
Broomberg said one problem was that the 
gap between leading generic products and 
leading ‘original’ brand-name products was 
far narrower than in most international 
environments, with many generics entering 
the SA market at a 20 - 30% price differential 
to the originator product, compared with up 
to 90% in developed countries, including the 
USA and countries in Europe. ‘The second 
problem is that our market is currently 
failing to take advantage of competitively 
priced generics. There are generics very 
competitively priced in most chronic 
categories, but somehow our members end 
up paying for much higher-priced equivalent 
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generics because of perversities in the 
supply chain.’ The most expensive generics 
dominate the market, and money moving 
between the manufacturers and dispensers 
was leading to the expensive products being 
dispensed when better-priced alternatives 
are available, which Broomberg described 
as ‘unacceptable’. He said the current Market 
Inquiry into Private Healthcare under the 
auspices of the Competition Commission 
was likely to investigate this. ‘It’s a classic 
example of market failure ... This kind of 
approach is damaging the medical scheme 
environment, and none of us can afford to 
take the short-term view. We’ve got to think 
about what happens when people drop out 
of medical aids because they can’t afford 
medicines and other high-cost interventions.’ 
Broomberg said that the rapid growth in the 
consumption of chronic medication (a windfall 
for the pharmaceutical companies, although 
not their fault) needed price adjustments and 
transparency to allow medical schemes to 
‘ensure that we can continue to support patients 
dealing with these diseases’. He revealed that 
Discovery Health’s MedXpress offering of free 
home and work delivery of drugs was being 
expanded to include the delivery of specialised 
high-cost medicines direct to doctors’ practices, 
with an initial focus on the oncology sector. 
The company was also combining all its units 
dealing with medicines into a single entity, 
enabling pharmaceutical and other companies 
to interact with Discovery Health through a 
highly efficient single point of contact. 
Boom in chronic 
medicine use
Discovery Health’s Head of Risk Manage-
ment Strategy, Ismail Rasool, highlighted 
the ‘enormous cost-containing potential’ 
if patients started to purchase the lowest-
priced generic equivalents currently on the 
market, putting the saving for the medical 
schemes that Discovery Health administers 
at approximately R500 million. Extrapolating 
this to the other major medical schemes 
would generate savings of up to R1.5 billion 
per annum just by shifting current dispensing 
towards lower-cost rather than the highest-
cost generics. This alone could reduce 
premiums by 1 - 2% per year. Putting figures 
to Broomberg’s assertion on the rapid growth 
of chronic medication consumption, he said 
that in 2003, 10% of Discovery Health Medical 
Scheme members had a chronic condition at 
an average age of 32. Last year (one decade 
later) this had increased to 20% at the same 
age. By the time members were 65, three out 
of five had a chronic condition, all underlying 
trends that he described as ‘very worrying’. In 
the year 2000, the scheme had 15/10 000 lives 
claiming more than half a million rands – by 
2014, this number had gone up five-fold to 
79/10 000, even after adjusting for inflation. 
‘So without younger, healthier lives coming 
into the system, there’s immense pressure on 
schemes to ensure cost-effective medicines 
are prescribed and dispensed.
‘The scheme’s total medicine expenditure 
(including hospital oncology) has gone up 
by 92% from R4 billion in 2008,’ Broomberg 
added. Among the diseases of lifestyle 
driving chronic medicines consumption 
were hypertension, diabetes and hyper-
lipidaemia. HIV was growing, but at 
no where near the same rate, with Discovery 
Health Medical Scheme now funding 38 000 
members for HIV-associated conditions. A 
particular concern is the impact of expensive 
new drugs for conditions such as cancer, 
rheumatoid arthritis and multiple sclerosis. 
These, together with a sub-set of similar 
novelty drugs, are predicted to increase in 
cost to R2.3 billion by 2020, from almost 
nothing in 2008. ‘We need to look at risk 
sharing and alternative reimbursement 
models to allow medical schemes to manage 
this cost explosion in a sustainable way.’
SA’s drug spend 
disproportionate to 
other similar countries
Discovery Health Medical Scheme data 
suggest that SA’s private healthcare system 
spends disproportionately more on medi-
cines, relative to total healthcare expenditure, 
than in the top ten comparative countries 
featured in a health systems performance 
study by the monitor group.
While the use of generics in hospitals 
had improved, there was ‘room for more’, 
Broomberg said. Further illustrating Broom-
berg’s concern about the high price point 
at which generics were being used, Rasool 
said that the average price difference (brand 
to generic) in the lowest price band was 
60%. The same difference when comparing 
the mid-range price band was 45%, while 
the top-priced comparison revealed a 39% 
difference. During open discussion, Paul 
Anley, CEO of Pharma Dynamics, one of 
SA’s foremost distributors of generic drugs, 
said that the reason for the large percentage 
price gap between brand name and generic 
drugs in the lowest price range was because 
they were not being actively marketed. ‘You 
have to be careful of just putting emphasis 
on price – because if you don’t tell anybody, 
you don’t get the switch!’ he warned.
Anley also said inefficiencies in SA 
legislation meant that patent ‘evergreening’ 
on original drugs (taking out multiple 
patents expiring at later and later dates to 
protect monopolies) worked to the great 
advantage of many drug companies. ‘They’re 
often challenged in foreign courts where the 
patents are quickly set aside. In SA, delays 
in a hearing for a revocation of a patent can 
take up to four years. We also don’t have 
dedicated patent judges and a skills base.’ 
Very often valid patents ‘on the books’ in 
SA had long been overturned in most other 
countries where generics then traded more 
freely. Anley said his calculations were that 
if one took the entire (private) branded drug 
market of R28 billion in SA and divided it 
by the number of packs sold, you got an 
average branded price of R219. A similar 
calculation in the generic market disclosed 
a figure of R73 – a differential of R146, or 
72% across the board. ‘That is the impact 
that generics are making in pharma,’ he said. 
Interviewed during a break, Anley said the 
total pharmaceutical market in SA stood 
at about R34 billion (R28 private sector 
and R5.5 billion state). He emphasised that 
when more expensive generics entered 
and gained traction in the market, sales 
volumes soon reached three times what 
the original brand was two or three years 
earlier. Anley cautioned against driving 
generic prices ‘down to the point where 
nobody uses them’, and said there was an 
inbuilt ‘catch 22’: low prices often meant that 
generic drug companies avoided spending 
money marketing these products – ‘that’s 
why they don’t move, not just because of 
price’. Rasool said Discovery Health’s data 
confirmed the initial market traction of 
generics. ‘But what we’re saying is that when 
people choose generics, it seems the most 
expensive ones are being used rather than 
the less expensive ones. This raises questions 
about the incentives being used to promote 
these more expensive generics,’ he said. 
Support smaller drug 
companies selling at 
more competitive prices 
– MediClinic
Anelia Bezuidenhout of MediClinic said 
that last year her hospital group put all 
their pharmaceutical products into groups 
with prior rankings in price bands before 
approaching their individual hospitals and 
‘It doesn’t make sense that 
many products, especially some 
generics, maintain such high 
prices and yet still have the 
largest market share. This defies 
market logic.’
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requesting them to ‘move to number one 
the better-priced products’. ‘In the beginning 
there were many stock-outs on the smaller 
drug companies, but slowly they increased 
their supplies and expanded their services to 
help us reach our goal. Yes, it’s true that your 
smaller company doesn’t deliver the required 
service, but over time they will!’ she stressed.
In his opening address Broomberg 
said that with medical inflation running 
at 10.3% in SA (three percentage points 
above the general consumer price index), 
6% was a result of changes in the price of 
goods and services – but the other 4.3% 
was due to more goods and services being 
consumed every year by the average medical 
scheme member. Discovery Health Medical 
Scheme currently spends R5 billion on ‘out-
of-hospital’ medications (R1.3 billion on 
‘in-hospital’ medications) with 15% of all 
claims in medicine, while 486 000 of the 
scheme’s 2.7 million members are registered 
for one or more chronic conditions. 
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